人附睾蛋白4与CA125联合检测对卵巢上皮癌的诊断价值

摘要

Objective: To investigated the level of application value of combined detection HE4 and CA125 in serum for the diagnosis of ovarian epithelial tumors.Method: 165 patients with ovarian tumor were selected,87 cases were ovarian epithelial cancers group,78 cases were benign ovarian tumors group and 50 cases were healthy women as control group,and all of them were detected by the methods of ELISA of CA125 in serum and HE4 in blood.Result: The level of HE4 in blood with epithelial ovarian cancer patients were significantly higher than that in benign ovarian tumor group and the control group,the difference was statistically significant(P<0.05). The sensitivity and accuracy of HE4 in blood were 87.3% and 92.3% respectively,the sensitivity and accuracy reached up to 96.5% and 97.4% by combined detection of HE4 in blood and CA125 in serum,the difference was statistically significant(P<0.05). Conclusion: The diagnostic rate of ovarian epithelial cancer can be improved significantly by combined detection of HE4 in blood and CA125 in serum.%目的：探讨人附睾蛋白4（HE4）联合血清CA125用于卵巢上皮性癌诊断的临床价值。方法：选取本院收治住院并经手术及病理检查确诊的卵巢上皮性肿瘤患者165例，用ELISA法检测血清中CA125水平和血液HE4水平，其中87例患者为卵巢上皮性癌组，78例患者为卵巢良性肿瘤组，50例同期健康体检女性为对照组。结果：卵巢上皮癌患者组血液中HE4水平明显高于卵巢良性肿瘤组及对照组，差异均有统计学意义（P<0.05）；血液中HE4检测卵巢上皮性癌的灵敏度、特异度分别为87.3%、92.3%，与血清CA125联合检测其灵敏度、特异度提高至96.5%、97.4%，差异有统计学意义（P<0.05）。结论：联合检测血液中HE4与血清CA125可显著提高卵巢上皮性癌的诊断率。